Amicus Therapeutics (FOLD) shares soared 6.4% in the last trading session to close at $8.48. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.7% gain over the past four weeks.The price rise can be attributed to growing investor optimism related to the strong uptake of the company’s lead product, Galafold and the combination drug, Pombiliti + Opfolda. In the first six months of 2025, Galafold generated sales worth $233.1 million, ...